Skip to content

US · PRGO · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Perrigo Company plc (PRGO) intrinsic value and stock valuation

$15.94as of 2026-11-21 · Mkt cap 1.84B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Perrigo Company plc DCF and intrinsic value

InvestorsCraft values PRGO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from PRGO’s statements →

Perrigo Company plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Dublin, DU D02 TY74 perrigo.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$4.25B+0.8% 5y CAGRd
20112025
Net income
-$-1.43B
20112025
Free cash flow
$145.1M-20.8% 5y CAGRd
20112025
Total equity
$2.94B-12.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$4.25B$4.37B$4.66B$4.45B$4.14B
Operating income$343.3M$112.9M$151.9M$78.9M$410.4M
Net income-$-1.43B-$-171.8M-$-12.7M-$-140.6M-$-68.9M
EPSd-$-10.29M-$-1.25M-$-93.87K-$-1.05M-$-515.72K
Operating cash flow$238.5M$362.9M$405.5M$307.3M$156.3M
Capital expenditure-$-93.4M-$-118.3M-$-101.7M-$-96.4M-$-152.1M
Free cash flow$145.1M$244.6M$303.8M$210.9M$4.2M
Total assets$8.54B$9.65B$10.8B$11B$10.4B
Total debt$3.97B$3.62B$4.07B$4.32B$3.69B
Net debt$3.44B$3.06B$3.32B$3.72B$1.83B
Total equity$2.94B$4.32B$4.77B$4.84B$5.15B
Cash and short-term investments$531.6M$558.8M$751.3M$600.7M$1.86B
Income statement
20252024202320222021
Revenue$4.25B$4.37B$4.66B$4.45B$4.14B
Cost of revenue$2.76B$2.83B$2.98B$3B$2.72B
Gross profit$1.49B$1.54B$1.68B$1.46B$1.42B
Research and development expenses$95.4M$112.2M$122.5M$123.1M$122M
Selling, general and administrative expenses$526.5M$1.11B$1.27B$1.21B$1.11B
Other expenses$529.3M$205M$131.4M$43.3M-$-227.6M
Operating expenses$1.15B$1.43B$1.53B$1.38B$1.01B
Cost and expenses$3.91B$4.26B$4.5B$4.37B$3.73B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$162.5M$187.8M$173.8M$156M$125M
Depreciation and amortization$337.5M$325.9M$359.5M$338.6M$312.2M
Ebitda-$-797.9M$433M$525M$355.5M$695.9M
Operating income$343.3M$112.9M$151.9M$78.9M$410.4M
Total other income/expenses, net-$-1.64B-$-193.6M-$-160.2M-$-218M-$-151.7M
Income before tax-$-1.3B-$-80.7M-$-8.3M-$-139.1M$258.7M
Income tax expense$104.4M$80M-$-3.9M-$-8.2M$389.6M
Net income-$-1.43B-$-171.8M-$-12.7M-$-140.6M-$-68.9M
Weighted average shares outstanding$138.5M$137.4M$135.3M$134.5M$133.6M
Weighted average diluted shares outstanding$138.5M$137.4M$135.3M$134.5M$133.6M
Balance sheet
20252024202320222021
Cash and short-term investments$531.6M$558.8M$751.3M$600.7M$1.86B
Net receivables$612.8M$642.3M$739.6M$697.1M$652.9M
Inventory$1.15B$1.08B$1.14B$1.15B$1.02B
Total current assets$2.8B$2.48B$2.83B$2.72B$3.86B
Property, plant and equipment, net$1.07B$1.09B$1.1B$1.14B$1.03B
Goodwill and intangible assets$4.41B$5.75B$6.52B$6.78B$5.15B
Long-term investments$25.4M$0.00$0.00$0.00$0.00
Total non-current assets$5.74B$7.17B$7.98B$8.3B$6.57B
Total assets$8.54B$9.65B$10.8B$11B$10.4B
Accounts payable$474.5M$495.2M$477.7M$537.3M$411.2M
Short-term debt$62.3M$36.4M$440.6M$64.6M$629.8M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.01B$1.04B$1.59B$1.11B$1.59B
Long-term debt$3.91B$3.58B$3.63B$4.26B$3.06B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.59B$4.28B$4.45B$5.06B$3.69B
Capital lease obligations$163M$0.00$0.00$217.9M$173.3M
Total liabilities$5.6B$5.33B$6.04B$6.18B$5.27B
Common stock$6.61B$6.73B$6.84B$6.94B$7.04B
Retained earnings-$-3.68B-$-2.25B-$-2.08B-$-2.07B-$-1.93B
Accumulated other comprehensive income (loss)$14.1M-$-162.4M$10.7M-$-27M$35.5M
Total equity$2.94B$4.32B$4.77B$4.84B$5.15B
Total investments$25.4M$0.00$0.00$0.00$0.00
Total debt$3.97B$3.62B$4.07B$4.32B$3.69B
Net debt$3.44B$3.06B$3.32B$3.72B$1.83B
Cash flow statement
20252024202320222021
Net income-$-1.4B-$-171.8M-$-12.7M-$-130.9M-$-68.9M
Depreciation and amortization$337.5M$325.9M$359.5M$338.6M$312.2M
Stock-based compensation$0.00$64.4M$68.8M$0.00$60.1M
Change in working capital-$-101.1M-$-74.7M-$-58.5M$20M-$-295.4M
Accounts receivable$30.7M-$-11.1M-$-57.1M$100K-$-159.7M
Inventory-$-61.1M$13.7M$19.4M-$-76.7M-$-2.4M
Accounts payable-$-28.7M$54.2M-$-65.9M$100.3M-$-7.9M
Net cash provided by operating activities$238.5M$362.9M$405.5M$307.3M$156.3M
Investments in property, plant and equipment-$-93.4M-$-118.3M-$-101.7M-$-96.4M-$-152.1M
Acquisitions, net$0.00$0.00$0.00-$-1.95B$1.49B
Net cash used for investing activities-$-75.4M$78.8M-$-77.5M-$-1.96B$1.28B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-159.3M-$-152.5M-$-149.7M-$-142.4M-$-129.6M
Net cash used for financing activities-$-220.5M-$-611M-$-187.2M$421.6M-$-178.7M
Net change in cash-$-27.2M-$-192.5M$150.6M-$-1.26B$1.23B
Cash at end of period$531.6M$558.8M$751.3M$600.7M$1.86B
Operating cash flow$238.5M$362.9M$405.5M$307.3M$156.3M
Capital expenditure-$-93.4M-$-118.3M-$-101.7M-$-96.4M-$-152.1M
Free cash flow$145.1M$244.6M$303.8M$210.9M$4.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Perrigo Company plc

        Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

        CEO
        Albert A. Manzone
        Employees
        8.1K
        Beta
        0.52

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Perrigo Company plc (PRGO)?

        Perrigo Company plc (PRGO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRGO undervalued?

        PRGO trades at a price of $15.94 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.